Iovance Biotherapeutics
IOVA
6.90
-0.41
-5.61%
Iovance Biotherapeutics
US · IOVA
#1864 by market cap
Listed 1970
6.90
-0.41
-5.61%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
Recent news
-
Rating change
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $15Market Newswire · 2026/9/17
-
Rating change
Jefferies Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $20Market Newswire · 2026/10/24
-
Rating change
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9Market Newswire · 2026/6/4
-
Earnings Flash (IOVA) Iovance Biotherapeutics, Inc. Reports Q3 Revenue $121.5M, Vs. FactSet Est of $116.0MMT Newswires · 2026/11/5
-
Rating change
Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $14Market Newswire · 2026/2/26
-
Rating change
Analysts Offer Insights on Healthcare Companies: Actuate Therapeutics, Inc. (ACTU), Iovance Biotherapeutics (IOVA) and Otsuka Holdings Co (OtherOTSKF)TipRanks · 2026/4/22
-
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/10/30
-
Rating change
TD Cowen Initiates Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $10Market Newswire · 2026/8/25
-
Rating change
Citizens JMP Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $8Market Newswire · 2026/8/8
-
Rating change
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $15 to $20Market Newswire · 2026/9/30
-
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $20Market Newswire · 2026/11/11
-
Rating change
Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16Market Newswire · 2026/4/11
-
Rating change
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11Market Newswire · 2026/7/20
-
Rating change
Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $11Market Newswire · 2026/8/18
-
Rating change
Goldman Sachs Upgrades Iovance Biotherapeutics(IOVA.US) to Buy Rating, Raises Target Price to $15Market Newswire · 2026/9/24
-
Rating change
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $7 to $13Market Newswire · 2026/8/7
-
Rating change
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $14Market Newswire · 2026/5/8
-
Citizens JMP Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $12Market Newswire · 2026/11/6
-
Rating change
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2026/10/13
-
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $19Market Newswire · 2026/11/6
-
Rating change
Baird Downgrades Iovance Biotherapeutics(IOVA.US) to Hold Rating, Cuts Target Price to $4Market Newswire · 2026/2/25
-
Rating change
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Erasca (ERAS) and Tempus AI, Inc. Class A (TEM)TipRanks · 2026/2/25
-
Rating change
Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Hold RatingMarket Newswire · 2026/2/25
-
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $20Market Newswire · 2026/10/30
-
Rating change
Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Sell Rating, Raises Target Price to $2Market Newswire · 2026/2/5
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:59:47 · For reference only, not investment advice and not tailored to your situation.
Iovance Biotherapeutics discussion 0 comments